Artificial Intelligence
BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia
<!– Name:DistributionId Value:8846370 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:4573 –> <!– Name:CustomerId Value:1204510 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:3cbe582f-cde4-49d2-968e-9c32acd99867 –>
Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™
Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates seen in SERENITY I and II
BXCL501 was well tolerated and demonstrated favorable safety results supporting potential for at-home use
SERENITY III Part 2 planned as an adaptive trial design with 60mcg and 80mcg to potentially address agitation spectrum for patients at home
Company to hold conference today at 8 a.m. ET
NEW HAVEN, Conn., May 25, 2023 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced promising results for BXCL501, the Company’s proprietary, orally dissolving film of dexmedetomidine under investigation for the treatment of agitation, in Part 1 of its Phase 3 SERENITY III trial conducted in institutional settings for acute treatment of bipolar disorders- or schizophrenia-associated agitation. These results are expected to enable the initiation of Part 2 for at-home use. BXCL501 would represent the first-ever FDA approved therapy for at-home use in this indication, if approved.
SERENITY III is a two-part, double-blinded, placebo-controlled pivotal study designed to evaluate BXCL501 in acutely agitated adult patients with bipolar disorders or schizophrenia for at-home use. Part 1 was similar to SERENITY I and II in design and assessed the efficacy and safety of a 60mcg dose using the same primary and secondary endpoints with patients in a monitored medical setting, as surrogates for the home setting. Patients enrolled in Part I were expected to have a relatively higher level of agitation than the home-based patient population expected to be enrolled in Part 2. Patients in Part 1 were evaluated with half (60mcg) of the already-approved 120mcg dose (IGALMI™) to enhance safety for the targeted at-home setting.
“We are pleased with the outcome and progression of our land-and-expand strategy, which we believe moves us closer to addressing up to an additional 23 million annual agitation episodes in bipolar disorder and schizophrenia patients in the at-home setting. This would potentially more than double our current market opportunity, if approved. Treatment in the early stages of agitation at home could significantly benefit patients, caregivers, and hospital systems by reducing the need for emergency room visits and associated treatment costs,” said Vimal Mehta, CEO of BioXcel Therapeutics. “We believe the entirety of BXCL501’s clinical dataset generated, along with our upcoming Alzheimer’s-related agitation milestones, could transform the agitation landscape for a broad spectrum of neuropsychiatric patients.”
Clinically meaningful efficacy results were observed with half (60mcg) of the lowest approved dose of IGALMI. In addition, greater than 50% PEC response rate was achieved, with responder rate dose-proportionally consistent with those observed in SERENITY I and II trials. Although the primary efficacy endpoint was not statistically significant at 2 hours (p=0.077), BXCL501 separated from placebo at 4 hours (p=0.049).
The study results suggested a broad safety margin with no reported serious adverse events (SAEs). The principal finding relates to the favorable safety results relative to those observed in studies evaluating the higher approved doses (120mcg and 180mcg). These data provide a clear path for initiating SERENITY III Part 2, to pursue approval in the at-home setting. Alignment has been obtained with the FDA for 60mcg and repeat dosing for Part 2.
“Overall, the 60mcg dose appears to be well-tolerated with safety results comparable to placebo, which is favorable for testing in the at-home setting. In the real world, physicians adapt their treatment approach based on both the patient and the underlying situation,” said Dr. John Krystal, M.D., the Robert L. McNeil, Jr. Professor of Translational Research and Chair of the Department of Psychiatry at Yale School of Medicine. “Therefore, I believe the strategy for Part 2 of the trial is well-suited to evaluate the value of BXCL501 for treating the continuum of agitation occurring at home.”
Summary of Topline Results from Part 1 of SERENITY III
- Efficacy Results: For the primary endpoint, at 2 hours post-dose, the change in PEC differed from that with placebo, but did not reach statistical significance, with a p-value of 0.077. At 4 hours post-dose, the p-value was 0.049. 52% were PEC responders by 2 hours post-dose (p = 0.019 versus placebo). The proportion responding was greater than with placebo as early as 1 hour (p = 0.035) and remained so through 4 hours. The proportion responding by CGI-I assessment (achieving a score of 1 or 2, ‘Very much improved’ or ‘Much improved’, respectively) was greater than with placebo at 2 hours post dose (p = 0.039).
- Safety and Tolerability Results: The 60mcg dose was well tolerated and there were no reported serious adverse events. All adverse events were reported as mild to moderate, with none of severe intensity. No adverse events required medical intervention or monitoring. The most commonly reported adverse event was somnolence, defined as feeling drowsy, sleepy, fatigued, or sluggish, which occurred in 13% of the 60mcg arm as opposed to 7% in the placebo group. Other adverse events reported in order of incidence for 60mcg and greater than with placebo were oral paresthesia or oral hypoesthesia (6% vs 4% placebo), dry mouth (5% vs 3% for placebo) and dizziness (3% vs 1% for placebo). Cardiovascular-related adverse events in the 60mcg group entailed 1 report of hypotension (0 in placebo), 1 of orthostatic hypotension (0 in placebo), and no reports of bradycardia or other cardiovascular adverse events in either group.
SERENITY III Part 1 Efficacy Results:
| Data | SERENITY III Part 1 | SERENITY I and II | ||||||
| Effect at 120 minutes (Primary Endpoint) |
Placebo (n=100) |
BXCL501 60 mcg (n=101) |
IGALMI™ 120 mcg (SERENITY I n=129)3 (SERENITY II n=126)4 |
IGALMI™ 180 mcg (SERENITY I n=125)3 (SERENITY II n=126)4 |
Placebo (SERENITY I n = 126)3 (SERENITY II n = 126)4 |
|||
| Reduction in PEC Score vs. Baseline LSM (SE) |
-3.8 (0.4) 2 hours -4.3 (0.4) 4 hours |
-4.8 (0.4) (p = 0.077) 2 hours -5.4 (0.4) (p = 0.049) 4 hours |
SERENITY I: -8.5 (0.4) SERENITY II: -9.1 (0.4) |
SERENITY I: -10.3 (0.4) SERENITY II: -10.4 (0.4) |
SERENITY I: -4.8 (0.4) SERENITY II: -5.0 (0.4) |
|||
| PEC Response Rate1 | 36 | % | 52% (p = 0.019) | SERENITY I: 81% SERENITY II: 79% |
SERENITY I: 90% SERENITY II: 92% |
SERENITY I: 48% SERENITY II: 48% |
||
| CGI-I Response Rate2 | 26 | % | 39% (p = 0.039) | SERENITY I: 66% SERENITY II: 70% |
SERENITY I: 86% SERENITY II: 87% |
SERENITY I: 36% SERENITY II: 38% |
||
1 PEC Response Rate: % of patients achieving ≥40% reduction in PEC scores by 2 hours
2 CGI-I Response Rate: % of patients assessed as ‘Very Much Improved, or ‘Much Improved’ by CGI-I at 2 hours
3 All comparisons p < 0.0001 in agitated patients with Schizophrenia (SERENITY 1), IGALMI™ Package insert, data on file and Citrome L, Preskorn SH, Lauriello J, et al. Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial. J Clin Psychiatry. 2022;83(6). doi:10.4088/JCP.22m14447.
4 All comparisons p < 0.0001 in agitated patients with Bipolar I or II Disorders (SERENITY 2), IGALMI™ Package insert, data on file and Preskorn SH, Zeller S, Citrome L, et al. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. JAMA. 2022;327(8):727-736. doi:10.1001/jama.2022.0799
Adverse Events Reported in SERENITY III Part 1 and in SERENITY I and II:
| Adverse Event | SERENITY III Part 1 | SERENITY I and II | |||||
| BXCL501 60mcg N = 101 |
Placebo N = 100 |
IGALMI™ 120mcg3 N = 255 |
IGALMI™ 180mcg3 N = 252 |
Placebo N = 2523 |
|||
| Somnolence1 | 13 (13) | 7 (7) | 56 (22) | 57 (23) | 16 (6) | ||
| Oral paresthesia or oral hypoesthesia | 6 (6) | 4 (4) | 14 (5) | 18 (7) | 2 (1) | ||
| Dizziness | 3 (3) | 1 (1) | 10 (4) | 15 (6) | 2 (1) | ||
| Hypotension | 1 (1) | 0 | 14 (5) | 13 (5) | 0 | ||
| Orthostatic hypotension | 1 (1) | 0 | 7 (3) | 13 (5) | 1 (0) | ||
| Dry mouth | 5 (5) | 3 (3) | 19 (7) | 11 (4) | 3 (1) | ||
| Nausea | 2 (2) | 1 (1) | 6 (2) | 7 (3) | 4 (2) | ||
| Bradycardia | 0 | 0 | 5 (2) | 5 (2) | 0 | ||
| Abdominal discomfort2 | 0 | 0 | 0 (0) | 6 (2) | 1 (0) | ||
1 Somnolence includes the terms feeling drowsy, feeling sleepy, fatigue and sluggishness
2 Abdominal discomfort includes dyspepsia, gastroesophageal reflux disease
3 IGALMI™ (dexmedetomidine) USPI, July 2022
No SAEs observed
The adverse events (AEs) listed correspond to those in the label for IGALMI. No other AEs were observed that would fulfill the criteria for inclusion in the AE table (at least 2% and greater than with placebo).
“We chose half of the lowest approved IGALMI dose, 60mcg, with the goal of increasing the margin of safety while supporting efficacy for at-home use,” said Robert Risinger, M.D., Chief Medical Officer, Neuroscience, of BioXcel Therapeutics. “We believe these results have opened the therapeutic window for BXCL501’s potential use at home for bipolar- and schizophrenia-related agitation. This is essential in the journey of dexmedetomidine. It was originally sequestered in the surgical unit as an anesthetic, then approved by the FDA as IGALMI to treat agitation in adult patients with schizophrenia or bipolar disorders in medical settings, before being investigated now for at-home use. These results support our SERENITY III Part 2 development path for use at home, where agitation typically originates and escalates prior to requiring emergency care.”
At-Home Agitation Market Insights1-4
There are approximately 39 million annual episodes of agitation associated with bipolar disorders or schizophrenia in adults that occur in the U.S. Of these, an estimated 23 million (~60%) episodes occur outside of a medical institution.
- Patients report feeling out of control and helpless when agitation episodes occur at home.
- Episodes may occur three times a month on average, with the majority of them escalating to moderate or severe.
- Physicians underdiagnose and undertreat these episodes in a community setting, with only a third of patients receiving prescription drugs, which are off-label and often suboptimal, for their agitation symptoms.
- In a market survey, patients indicated they would take BXCL501 for 80% of their agitation episodes.
- 90% of those patients indicated they would take BXCL501 when they feel an episode coming on or when an episode begins.
The Company plans to proceed with SERENITY III Part 2 using an adaptive trial design with 60mcg or greater dose, such as 80mcg, which has demonstrated statistical significance in the Company’s prior Phase 1b trial. The design may include potential repeat dosing as required to address the entire agitation spectrum for patients at home.
Conference Call
BioXcel Therapeutics will host an investor conference call and webcast May 25, 2023 at 8 a.m. ET to discuss the pivotal Phase 3 SERENITY III Part 1 trial results. To access the call, please dial 877-407-5795 (domestic) or 201-689-8722 (international). A live webcast will be available on the Investors section of the company’s website, www.bioxceltherapeutics.com, and a replay will be available through at least August 25, 2023. In addition, a slide presentation of the SERENITY III Part 1 top-line results and key market insights has been posted on the Events and Presentations page of the company’s website.
BioXcel Therapeutics may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors sections of its website at www.bioxceltherapeutics.com. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Email Alerts” option under the News/Events menu of the Investors & Media section of its website.
*About the PEC (PANSS-EC or the Positive and Negative Syndrome Scale-Excitatory Component) Score for Agitation
The PEC total score is a validated regulatory endpoint for measuring acute agitation in schizophrenia and bipolar patients. This scale is used in clinical research to quantify the severity of a patient’s acute agitation. The PEC rating evaluates 5 elements associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC total score is the sum of these 5 elements and thus ranges from 5 to 35.
About BXCL501
BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BioXcel Therapeutics believes that BXCL501 potentially targets an important mediator of agitation, and the Company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders. BXCL501 is under investigation for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting, for the acute treatment of Alzheimer’s-related agitation, and as an adjunctive treatment for Major Depressive Disorder. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.
About IGALMI™ (dexmedetomidine) sublingual film
INDICATION
IGALMI™ (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.
IMPORTANT SAFETY INFORMATION
IGALMI can cause serious side effects, including:
- Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint.
- Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations.
- Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI.
- Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours.
The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.
These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects.
Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids.
Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or [email protected].
Please see full Prescribing Information at igalmi.com.
About Agitation Associated with Schizophrenia and Bipolar Disorder
Agitation is a common and difficult-to-manage symptom associated with bipolar I or II or schizophrenia. Early identification and prompt intervention to relieve agitation are essential to avoid symptomatic escalation and the emergence of aggression. Expert consensus best-practice guidelines have recommended that agitation should be treated by a combination of behavioral calming techniques, verbal de-escalation, and medications that are voluntarily accepted by patients without coercion. The goal of using medication is to calm the patient so that he or she can be more accurately assessed by clinicians. Medication used in this manner is consistent with current guidelines, which state that the proper endpoint of medication administration is calming without inducing sleep. This approach may help avoid the costly and traumatic use of coercive techniques like physical restraint and seclusion, which may result in admission and prolonged hospitalization.1
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. The Company’s commercial product, IGALMI™ (developed as BXCL501), is a proprietary, sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose. For more information, please visit igalmi.com and also see the IGALMI full Prescribing Information. BXCL501 is under evaluation for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for acute treatment of agitation associated with probable Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The safety and efficacy of BXCL501 for these uses have not been established. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, oral systemic innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The safety and efficacy of BXCL502 and BXCL701 have not been established. For more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, the Company’s expected timing of, trial design and data results from, future clinical trials of BXCL501, in particular for the SERENITY III Part 2 trial, potential safety and tolerability features of BXCL501, the potential addressable market for BXCL501 and the potential benefits from treatment with BXCL501. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited experience in drug discovery and drug development; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502 and BXCL701 and other product candidates; its limited experience in marketing and selling drug products; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact Information
Corporate
BioXcel Therapeutics
Erik Kopp
1.203.494.7062
[email protected]
Investor Relations
BioXcel Therapeutics
Brennan Doyle
1.475.355.8462
[email protected]
Media
David Schull or Scott Stachowiak
Russo Partners
(858) 717-2310
[email protected]
[email protected]
Source: BioXcel Therapeutics, Inc.
IGALMI™ is a trademark of BioXcel Therapeutics, Inc.
BT BIOXCEL THERAPEUTICS is a registered trademark of BioXcel Therapeutics, Inc.
All other trademarks are the properties of their respective owners.
Copyright © 2023, BioXcel Therapeutics, Inc. All rights reserved.
References
- Data on file. BioXcel Therapeutics, Inc. New Haven, CT December 2020.
- Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535-1540.
- National Institute of Mental Health. Prevalence of bipolar disorder in adults. November 2017. Accessed December 16, 2022. https://www.nimh.nih.gov/health/statistics/bipolar-disorder.
- InVibe Feb 2023
Artificial Intelligence
Wondershare DemoCreator Unveils V8.0: Accelerating Video Creation and Editing with Innovative AI Features
VANCOUVER, BC, May 28, 2024 /PRNewswire/ — Wondershare DemoCreator, the leading software for screen recording and video editing, proudly announces the release of its latest version DemoCreator 8.0. DemoCreator 8.0 supercharges the broad spectrum of educational and instructional video content, empowered by its updated AI enhancements. These advancements position DemoCreator 8.0 as a top player and pioneering video tool for educators, marketers, and influencers.
The PR Director at Wondershare, Iris L. stated, “DemoCreator has always been dedicated to simplifying video creation process, with version 8.0, we’ve introduced advanced AI technologies to enhance user experience and productivity. We believe that with our continuous effort, DemoCreator will remain the top choice for creators, helping them achieve greater success in sharing content.”
Key Upgrades in DemoCreator 8.0:
New Design: Upgraded UI and Magic Tools for enhanced efficiency.
New Template: Create captivating videos with refined templates in a few clicks.
Auto Subtitles: Generate accurate subtitles with trendy animations in over 90 languages.
Text to Speech: Convert text to human-like speech with 120+ voice options.
AI Voice Changer: Change voices into 24 different characters.
AI Object Remover: Remove unwanted elements from videos and images with one click.
AI Vocal Remover: Separate background sounds and vocals for noise reduction.
AI Beauty Filter: Six pre-set beauty effects with customization options.
Brand Kits: Create a unique brand kit with a customizable intro, outro, and logo.
Technological Upgrades: 50% faster video rendering and 200% faster export speeds.
Compatibility:
Wondershare DemoCreator is compatible with Windows and soon with Mac, with pricing starting at $29.99. For free trials and downloads, please visit DemoCreator’s website or follow us on YouTube, Facebook, Twitter, and Instagram to stay updated.
About Wondershare:
Wondershare is globally recognized as a software company committed to delivering innovative solutions for personal and professional use. As a leader in creativity and productivity products, Wondershare has received prestigious awards from organizations such as The Shorty Awards, G2, and GetApp. At Wondershare, the mission is to empower individuals to pursue their passions and build a more creative world. With over 100 million users across 150 countries, users can access a wide range of software solutions for video editing, PDF editing, data recovery, diagram and mind mapping, and more. Wondershare strives to provide high-quality, user-friendly software that enables individuals and businesses to bring their creative ideas to life.
Media Contacts
Iris [email protected]
Photo – https://mma.prnewswire.com/media/2422854/Wondershare.jpg
Logo – https://mma.prnewswire.com/media/1274391/wondershare_LOGO.jpg
View original content:https://www.prnewswire.co.uk/news-releases/wondershare-democreator-unveils-v8-0-accelerating-video-creation-and-editing-with-innovative-ai-features-302156318.html
Artificial Intelligence
Fingerprint Sensor Market worth $5.9 billion by 2029 – Exclusive Report by MarketsandMarkets™
CHICAGO, May 27, 2024 /PRNewswire/ — The Fingerprint Sensor Market is projected to grow from USD 4.2 billion in 2024 and is estimated to reach USD 5.9 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.0% from 2024 to 2029 according to a new report by MarketsandMarkets™. The rise in number of identity threats is one of the key factors leading to emergence of fingerprint technologies. Identity theft refers to the illegal acquisition of an individual’s personal or financial details to perpetrate fraud, including unauthorized transactions. It occurs through various methods and inflicts harm on victims’ credit, finances, and reputation.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=169519533
Browse in-depth TOC on “Fingerprint Sensor Market” 100 – Tables60 – Figures200 – Pages
Fingerprint Sensor Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 4.2 billion in 2024
Estimated Value by 2029
$ 5.9 billion
Growth Rate
Poised to grow at a CAGR of 7.0%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By technology, sensor technology, type, end-use application and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Sensor performance limitations
Key Market Opportunities
Increased adoption of IoT-based biometric technology
Key Market Drivers
Rise in number of identity threats leading to emergence of fingerprint technologies
Area & Touch sensors in the sensor type segment is expected to witness higher CAGR during the forecast period.
Area & touch sensors segment is expected to witness a higher CAGR during the forecast period in the fingerprint sensor market. These sensors activate upon physical contact with an object or individual and are more sensitive compared to traditional buttons or manual controls. They provide users with a seamless and responsive experience, making them ideal for modern electronic devices where sleek design and user convenience are paramount.
The 2D segment in the fingerprint sensor market is expected to capture higher share during the forecast period.
2D sensor technology captures a person’s fingerprint pattern, including ridges and valleys, in two dimensions using a single plane of lasers to measure the X and Y dimensions. This technology is primarily utilized for detection and ranging tasks. Due to its affordability, 2D sensor technology remains popular among OEMs, especially in mobile devices requiring compact sensors to meet the preferences of end users. Key players such as Synaptics Incorporated (US), Fingerprints (Sweden), and Shenzhen Goodix Technology Co., Ltd. (China) offer 2D sensors for various consumer electronics and applications.
Ultrasonic is expected to witness the highest CAGR in the fingerprint sensor market during the forecast period.
Ultrasonic fingerprint sensors utilize sound waves to penetrate the outer layers of the skin, enabling the capture of three-dimensional (3D) details and distinct fingerprint characteristics like ridges and sweat pores. Unlike current capacitive touch-based fingerprint technologies, ultrasonic sensors can read both the epidermal and dermal layers of the skin, allowing for the capture of fine details. Consequently, these sensors can accurately read wet fingers or those with ruptured or damaged skin. The continuous advancements in sensing technology are expected anticipated to propel the growth of the ultrasonic fingerprint sensor market. In January 2022, vivo (China) announced the 1000 9 Pro smartphone with Qualcomm’s 3D Sonic Max ultrasonic fingerprint sensor. The new smartphone is based on Snapdragon 8 Gen 1 processor. The Qualcomm 3D Sonic Max in the IQ00 9 Pro enables a super-fast one-tap fingerprint registration process.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=169519533
North America is expected to hold the second largest share of the fingerprint sensor industry during the forecast period.
North America is driven by the increasing adoption of biometric authentication across various sectors, particularly consumer electronics, government, and commercial domains. The US Department of Homeland Security (DHS) has been actively promoting the use of biometric technologies, including fingerprint sensors, for enhancing border security and immigration processes. The DHS’s Biometric Entry-Exit Program has facilitated the deployment of fingerprint scanners at various ports of entry, contributing to the market’s growth in the region. According to November 2023 statistics by US Department of Homeland Security (DHS), 1,018,349 persons obtained lawful permanent resident status in year 2022 compared to 740,002 persons in 2021, which is 37.6% y-o-y increase.
Key Players
Major vendors in the fingerprint sensor companies include Shenzhen Goodix Technology Co., Ltd. (China), Fingerprints (Sweden), Synaptics Incorporated (US), Apple Inc. (US) NEXT Biometrics (Norway), Novatek Microelectronics Corp. (Taiwan), Qualcomm Technologies, Inc. (US) among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=169519533
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports:
Access Control Market by Offering (Hardware-Card-based, Biometric, & Multi-technology Readers, Electronics Locks, Controllers; Software; Services), ACaaS (Hosted, Managed, Hybrid), Vertical and Region – Global Forecast to 2029
Biometric System Market Size, Share & Industry Growth Analysis Report by Authentication Type (Single Factor, Fingerprint, Iris, Face, Voice; Multi-factor), Type (Contact-based, Contactless, Hybrid), Offering Type, Mobility, Vertical & Region, 2027
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/fingerprint-sensors-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/fingerprint-sensors.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fingerprint-sensor-market-worth-5-9-billion-by-2029—exclusive-report-by-marketsandmarkets-302155899.html
Artificial Intelligence
Cloud Analytics Market worth $118.5 billion by 2029- Exclusive Report by MarketsandMarkets™
CHICAGO, May 27, 2024 /PRNewswire/ — The market for cloud analytics has a promising future because of the acceptance of real-time analytics, the expansion of big data and IoT, and the integration of AI and machine learning. Its adoption across multiple industries will be further accelerated by improved security, edge computing integration, and user-friendly platforms that prioritise data-driven decision-making and customised customer experiences.
The Cloud Analytics Market is estimated to grow from USD 35.7 billion in 2024 to USD 118.5 billion in 2029, at a CAGR of 27.1% during the forecast period, according to a new report by MarketsandMarkets™. Cloud analytics revolutionizes data storage and analysis by harnessing the power of the cloud. By storing and analyzing data in the cloud, businesses can extract actionable insights crucial for both SMEs and large enterprises. This approach facilitates identifying patterns, predicting future outcomes, and gaining valuable insights. Cloud analytics offers an opportunity to consolidate data and convert it into actionable intelligence while reducing procurement and maintenance costs. It involves utilizing both cloud-stored data and the rapid computing power of the cloud for faster analytics. However, with cloud infrastructure, organizations gain access to scalable, secure, and efficient data storage and processing solutions, enabling them to meet the demands of big data and drive innovation.
Browse in-depth TOC on “Cloud Analytics Market”
333 – Tables 66 – Figures342 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=959
Scope of the Report
Report Metrics
Details
Market size available for years
2019–2029
Base year considered
2023
Forecast period
2024–2029
Forecast units
USD Billion
Segments Covered
Offering, Data Type, Data Processing, Vertical, and Region
Geographies covered
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America
Companies covered
IBM (US), SAS Institute (US), Oracle (US), Google (US), Microsoft (US), Teradata (US), Salesforce (US), AWS (US), NetApp (US), Qilk (US), Sisense (US), SAP (Germany), Atos (France), Altair (US), Microstrategy (US), Tibco Software (US), Hexaware Technologies (India), Zoho (India), Rackspace Technology (US), Splunk (US), Cloudera (US), Domo (US), Hewlett Packard Enterprise (US), Incorta (US), Tellius (US), Rapyder (US), Hitachi Vantara (US), Board International (Switzerland), Ridge (Israel), Jaspersoft (US), Yellowfin (Australia), Deonodo (US), GoodData (US), Thoughtspot (US), and Infogain (US)
By offering the services segment to account for higher CAGR during the forecast period
Services segment in the Cloud Analytics Market have experienced remarkable growth in the Cloud Analytics Market, fueled by the increasing adoption of data-driven decision-making across industries. These services offer businesses the capability to analyze vast amounts of data stored in the cloud swiftly and efficiently, enabling them to extract valuable insights for strategic planning, optimization, and innovation. With the scalability and flexibility of cloud infrastructure, analytics services can accommodate diverse data types and analytical workloads, empowering organizations to derive actionable intelligence from their data in real time. As businesses continue to prioritize agility and competitiveness, the demand for cloud analytics services is expected to soar, driving further innovation and expansion in the Cloud Analytics Market landscape.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=959
By Type, advanced analytics solution is expected to hold the largest market size for the year 2024
The surge in advanced analytics adoption within the Cloud Analytics Market is reshaping the landscape of data-driven decision-making. Organizations across diverse sectors are increasingly turning to advanced analytics solutions hosted on cloud platforms to extract deeper insights from their data. This trend stems from the growing realization that traditional analytics methods are no longer sufficient to cope with the complexities of modern data ecosystems. Advanced analytics, powered by machine learning algorithms, predictive modeling, and AI, offer unparalleled capabilities to uncover hidden patterns, forecast trends, and optimize business processes. By leveraging the scalability, flexibility, and cost-effectiveness of cloud infrastructure, businesses can access powerful analytics tools without the burden of hefty upfront investments in hardware and software. As a result, the Cloud Analytics Market is witnessing rapid expansion, fueled by the transformative potential of advanced analytics in driving innovation, enhancing operational efficiency, and gaining a competitive edge in today’s data-driven economy.
By Vertical, Healthcare & Life Sciences is projected to grow at the highest CAGR during the forecast period
The healthcare and life sciences sector is experiencing a transformative shift with the emergence of cloud analytics. This technology integrates vast amounts of data from various sources, including electronic health records, wearable devices, and genomic information, to derive meaningful insights and drive informed decision-making. Cloud analytics offers scalability, flexibility, and cost-effectiveness, enabling organizations to efficiently manage and analyze massive datasets that were previously challenging to handle. By leveraging advanced analytics techniques such as machine learning and predictive modeling, healthcare providers and life sciences companies can enhance patient care, optimize clinical workflows, and accelerate drug discovery processes. Moreover, cloud-based analytics facilitates collaboration among researchers, clinicians, and stakeholders, fostering innovation and driving advancements in personalized medicine and population health management. As the industry continues to embrace digital transformation, cloud analytics stands as a cornerstone for unlocking the full potential of data-driven healthcare and life sciences initiatives.
Asia Pacific is expected to grow at the highest CAGR during the forecast period
The Asia Pacific region is experiencing a significant surge in the adoption of cloud analytics, reshaping how businesses make data-driven decisions. Companies spanning various industries are embracing cloud-based analytics platforms to optimize operations, foster innovation, and gain actionable insights. Additionally, the ubiquitous nature of mobile devices and internet connectivity has heightened the demand for real-time analytics accessible from anywhere. Governments and enterprises recognize the strategic value of harnessing analytics to maintain competitiveness in the global marketplace. Consequently, investments in cloud analytics technologies and talent development are escalating, positioning the Asia Pacific region as a pivotal player in the global cloud analytics landscape.
Top Key Companies in Cloud Analytics Market:
The significant cloud analytics software and service providers include IBM (US), SAS Institute (US), Oracle (US), Google (US), Microsoft (US), Teradata (US), Salesforce (US), AWS (US), NetApp(US), Qilk(US), Sisense (US), SAP (Germany), Atos (France), Altair (US), Microstrategy (US), Tibco Software (US), Hexaware Technologies (India), Zoho (India), Rackspace Technology (US), Splunk (US), Cloudera (US), Domo (US), Hewlett Packard Enterprise (US), Incorta (US), Tellius (US), Rapyder (US), Hitachi Vantara (US), Board International (Switzerland), Ridge (Israel), Jaspersoft (US), Yellowfin (Australia), Deonodo(US), GoodData(US), Thoughtspot (US), and Infogain (US). These companies have used organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the Cloud Analytics Market.
Recent Developments:
In January 2024, Salesforce unveiled fresh Commerce Cloud tools leveraging generative AI and data-driven insights, enhancing every customer interaction for heightened loyalty and revenue growth.In February 2024, IBM and Wipro strengthened their collaboration to offer clients expanded AI services and support. This collaboration aims to utilize AI technologies to tackle various business challenges and foster innovation across industries.In June 2023, Salesforce and Google formed a partnership. The partnership between Salesforce and Google focuses on integrating Google’s AI capabilities into Salesforce’s products, enhancing their analytics offerings.In May 2023, Microsoft launched Microsoft Fabric Data Analytics which is a cutting-edge platform tailored for the AI era, facilitating seamless integration of analytics and AI capabilities into data processing workflows. It streamlines data ingestion, preparation, and analysis, enabling organizations to derive actionable insights efficiently.In August 2022, Teradata introduced VantageCloud Lake, a cloud-native service designed to simplify data lakes for businesses, enabling seamless management and analytics of vast data sets.Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=959
Cloud Analytics Market Advantages:
Platforms for cloud analytics offer scalable resources, making it simple for companies to modify their requirements for storage and processing power in response to demand. Because of its adaptability, businesses may manage different data volumes without having to make costly infrastructure investments.Businesses can lower their capital hardware and software costs by utilising cloud analytics. Pay-as-you-go cloud service pricing allows businesses to optimise their total IT expenditure by only paying for the resources they really utilise.Compared to on-premises systems, cloud analytics solutions may be implemented and deployed far more quickly. This speedy deployment shortens the time to insight, allowing companies to begin data analysis and value extraction right away.Platforms for cloud-based analytics enable remote access to analytics tools and data from any location with an internet connection. Team members can collaborate on data projects regardless of location thanks to this accessibility, which fosters teamwork.Advanced analytics features like machine learning, artificial intelligence, and predictive analytics are frequently included in cloud analytics solutions. Organisations can gain deeper insights and make better decisions with the aid of these technologies.Businesses can analyse data as it is generated with the use of cloud analytics solutions, which provide real-time data processing and analytics. Applications that need instant insights, like fraud detection, operational monitoring, and customer engagement, depend on this real-time capacity.Platforms for cloud analytics can easily interface with a range of data sources, such as databases, data lakes, outside apps, and Internet of Things gadgets. A unified perspective of corporate operations and thorough data analysis are guaranteed by this integration capabilities.Report Objectives
To define, describe, and predict the Cloud Analytics Market by offering, data type, data processing, vertical, and regionTo describe and forecast the Cloud Analytics Market, in terms of value, by region—North America, Europe, Asia Pacific, Middle East & Africa, and Latin AmericaTo provide detailed information regarding major factors influencing the market growth (drivers, restraints, opportunities, and challenges)To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall Cloud Analytics MarketTo profile key players and comprehensively analyze their market positions in terms of ranking and core competencies, along with detailing the competitive landscape for market leadersTo analyze competitive developments such as joint ventures, mergers and acquisitions, product developments, and ongoing research and development (R&D) in the Cloud Analytics MarketTo provide the illustrative segmentation, analysis, and projection of the main regional marketsBrowse Adjacent Markets: Analytics Market Research Reports & Consulting
Related Reports:
Risk Analytics Market – Global Forecast to 2029
Retail Analytics Market- Global Forecast to 2029
Text to Video AI Market – Global Forecast to 2027
Contact Center Analytics Market- Global Forecast to 2027
Procurement Analytics Market- Global Forecast to 2026
Get access to the latest updates on Cloud Analytics Companies and Cloud Analytics Industry
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee Road Suite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cloud-analytics-market-worth-118-5-billion-by-2029–exclusive-report-by-marketsandmarkets-302155868.html
-
Artificial Intelligence4 days agoTitans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Uncategorized4 days agoGienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Artificial Intelligence4 days agoBybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Uncategorized4 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence4 days agoNorthern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
-
Artificial Intelligence6 days agoHONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Artificial Intelligence3 days agoIoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence3 days agoOverseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
